Skip to contentA
Abbott Laboratories
A
ABTAbbott Laboratories Q2 2020 · 10-Q
Revenue$7.33B$7.33B−8.2% vs Q2 2019 Net Income$537.00M$537.00M−46.6% vs Q2 2019 EPS Diluted$0.30$0.30−46.4% vs Q2 2019 Operating Income$672,000,000−44.3% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Abbott Laboratories · CIK 1800 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$680,000,000+14.9% Margins · derivedOperating margin9.2%−5.9 pt vs Q2 2019
Net margin7.3%−5.3 pt vs Q2 2019
ended Jun 30, 2020 · filed Jul 29, 2020 · 29 d after period end